

# Frederic Jj Bihel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4369464/publications.pdf>

Version: 2024-02-01

79  
papers

1,911  
citations

279798

23  
h-index

289244

40  
g-index

93  
all docs

93  
docs citations

93  
times ranked

2476  
citing authors

#	ARTICLE	IF	CITATIONS
1	The initial substrate-binding site of $\beta$ -secretase is located on presenilin near the active site. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 3230-3235.	7.1	208
2	New protease inhibitors prevent $\beta$ -secretase-mediated production of A $\beta$ 40/42 without affecting Notch cleavage. Nature Cell Biology, 2001, 3, 507-511.	10.3	181
3	Endogenous mammalian RF-amide peptides, including PrRP, kisspeptin and 26RFa, modulate nociception and morphine analgesia via NPPF receptors. Neuropharmacology, 2013, 75, 164-171.	4.1	90
4	6-endo-dig Cyclization of heteroarylesters to alkynes promoted by Lewis acid catalyst in the presence of Brønsted acid. Tetrahedron Letters, 2008, 49, 62-65.	1.4	81
5	The neuroprotector kynurenic acid increases neuronal cell survival through neprilysin induction. Neuropharmacology, 2013, 70, 254-260.	4.1	65
6	Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments. British Journal of Pharmacology, 2012, 165, 424-435.	5.4	64
7	t-BuXPhos: a highly efficient ligand for Buchwald-Hartwig coupling in water. Green Chemistry, 2014, 16, 4170-4178.	9.0	62
8	New 2-bromomethyl-8-substituted-benzo[c]chromen-6-ones. Synthesis and biological properties. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 135-138.	2.2	59
9	Discovery of a Subnanomolar Helical-Tridecapeptide Inhibitor of $\beta$ -Secretase. Journal of Medicinal Chemistry, 2004, 47, 3931-3933.	6.4	55
10	Fully Regiocontrolled Polyarylation of Pyridine. Journal of Organic Chemistry, 2014, 79, 908-918.	3.2	49
11	RF-amide neuropeptides and their receptors in Mammals: Pharmacological properties, drug development and main physiological functions. , 2016, 160, 84-132.		48
12	Synthesis of new 3-alkoxy-7-amino-4-chloro-isocoumarin derivatives as new $\beta$ -amyloid peptide production inhibitors and their activities on various classes of protease. Bioorganic and Medicinal Chemistry, 2003, 11, 3141-3152.	3.0	44
13	Buchwald-Hartwig reactions in water using surfactants. Tetrahedron, 2014, 70, 3413-3421.	1.9	42
14	TSPO Ligands Boost Mitochondrial Function and Pregnenolone Synthesis. Journal of Alzheimer's Disease, 2019, 72, 1045-1058.	2.6	38
15	New 3-Azido-3-deoxythymidin-5-yl-O-(1-Hydroxyalkyl) Carbonate Prodrugs: Synthesis and Anti-HIV Evaluation. Journal of Medicinal Chemistry, 2001, 44, 777-786.	6.4	35
16	Glucose: An Efficient Reducing Agent for a Copper(II)-Mediated Arylation of Primary Amines in Water. ChemSusChem, 2016, 9, 3244-3249.	6.8	30
17	Novel synthesis of 3,4-dihydro-5-bromo[1,4]oxazin-2-one derivatives, new protease inhibitor scaffold. Organic and Biomolecular Chemistry, 2003, 1, 793.	2.8	29
18	Design of potential new HIV protease inhibitors: enantioconvergent synthesis of new pyrrolidin-3-ol, and pyrrolidin-3-one peptide conjugates. Journal of the Chemical Society, Perkin Transactions 1, 2001, , 1421-1430.	1.3	28

#	ARTICLE	IF	CITATIONS
19	Direct Guanidinylation of Aryl and Heteroaryl Halides via Copper-Catalyzed Cross-Coupling Reaction. <i>Journal of Organic Chemistry</i> , 2012, 77, 417-423.	3.2	28
20	N-Heteroarylation of Chiral $\alpha$ -Aminoesters by Means of Palladium-Catalyzed Buchwald-Hartwig Reaction. <i>Journal of Organic Chemistry</i> , 2013, 78, 7930-7937.	3.2	28
21	The translocator protein ligand XBD173 improves clinical symptoms and neuropathological markers in the SJL/J mouse model of multiple sclerosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 3016-3027.	3.8	28
22	Fukuyama Cross-Coupling Approach to Isoprekinamycin: Discovery of the Highly Active and Bench-Stable Palladium Precatalyst POxAP. <i>Organic Letters</i> , 2019, 21, 844-848.	4.6	28
23	Human erythrocytes release ATP by a novel pathway involving VDAC oligomerization independent of pannexin-1. <i>Scientific Reports</i> , 2018, 8, 11384.	3.3	26
24	Structure-Activity Relationship Study around Guanabenz Identifies Two Derivatives Retaining Antiprion Activity but Having Lost $\alpha$ -2-Adrenergic Receptor Agonistic Activity. <i>ACS Chemical Neuroscience</i> , 2014, 5, 1075-1082.	3.5	25
25	Efficient and Mild Ullmann-Type N-Arylation of Amides, Carbamates, and Azoles in Water. <i>Chemistry - A European Journal</i> , 2017, 23, 13676-13683.	3.3	25
26	A bifunctional-biased mu-opioid agonist-neuropeptide FF receptor antagonist as analgesic with improved acute and chronic side effects. <i>Pain</i> , 2018, 159, 1705-1718.	4.2	25
27	Development of a Peptidomimetic Antagonist of Neuropeptide FF Receptors for the Prevention of Opioid-Induced Hyperalgesia. <i>ACS Chemical Neuroscience</i> , 2015, 6, 438-445.	3.5	22
28	Mitochondria modulatory effects of new TSPO ligands in a cellular model of tauopathies. <i>Journal of Neuroendocrinology</i> , 2020, 32, e12796.	2.6	22
29	Minimizing HCN in DIC/Oxyma-Mediated Amide Bond-Forming Reactions. <i>Organic Process Research and Development</i> , 2020, 24, 1341-1349.	2.7	21
30	Substituted thiazolamide coupled to a redox delivery system: a new $\beta$ -secretase inhibitor with enhanced pharmacokinetic profile. <i>Organic and Biomolecular Chemistry</i> , 2005, 3, 612-618.	2.8	19
31	RF313, an orally bioavailable neuropeptide FF receptor antagonist, opposes effects of RF-amide-related peptide-3 and opioid-induced hyperalgesia in rodents. <i>Neuropharmacology</i> , 2017, 118, 188-198.	4.1	18
32	Heteroarylguanidines as Allosteric Modulators of ASIC1a and ASIC3 Channels. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1357-1365.	3.5	18
33	Microwave-assisted cyclic amidine synthesis using TiCl <sub>4</sub> . <i>Organic and Biomolecular Chemistry</i> , 2006, 4, 3142.	2.8	17
34	TSPO ligands stimulate ZnPPiX transport and ROS accumulation leading to the inhibition of <i>P. falciparum</i> growth in human blood. <i>Scientific Reports</i> , 2016, 6, 33516.	3.3	17
35	Aminoguanidine Hydrazone Derivatives as Nonpeptide NPFF1 Receptor Antagonists Reverse Opioid Induced Hyperalgesia. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2599-2609.	3.5	17
36	Synthesis and Antiviral Activity of New Anti-HIV Amprenavir Bioisosteres. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 3321-3324.	6.4	16

#	ARTICLE	IF	CITATIONS
37	Design and synthesis of 3-aminophthalazine derivatives and structural analogues as PDE5 inhibitors: anti-allodynic effect against neuropathic pain in a mouse model. <i>European Journal of Medicinal Chemistry</i> , 2019, 177, 269-290.	5.5	16
38	Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors. <i>RSC Medicinal Chemistry</i> , 2021, 12, 828-870.	3.9	16
39	Development of sub-nanomolar dipeptidic ligands of neuropeptide FF receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 7471-7474.	2.2	14
40	Opioid adjuvant strategy: improving opioid effectiveness. <i>Future Medicinal Chemistry</i> , 2016, 8, 339-354.	2.3	14
41	Access to 4-Alkylaminopyridazine Derivatives via Nitrogen-Assisted Regioselective Pd-Catalyzed Reactions. <i>Journal of Organic Chemistry</i> , 2014, 79, 10311-10322.	3.2	13
42	The long-lasting love affair between the budding yeast <i>Saccharomyces cerevisiae</i> and the Epstein-Barr virus. <i>Biotechnology Journal</i> , 2015, 10, 1670-1681.	3.5	13
43	Effects of systematic N-terminus deletions and benzoylations of endogenous RF-amide peptides on NPFF1R, NPFF2R, GPR10, GPR54 and GPR103. <i>Peptides</i> , 2015, 71, 156-161.	2.4	13
44	New PDE4 inhibitors based on pharmacophoric similarity between papaverine and tofisopam. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 6567-6572.	2.2	12
45	A Yeast/Drosophila Screen to Identify New Compounds Overcoming Frataxin Deficiency. <i>Oxidative Medicine and Cellular Longevity</i> , 2015, 2015, 1-10.	4.0	12
46	Pharmacological characterization of the mouse NPFF2 receptor. <i>Peptides</i> , 2010, 31, 215-220.	2.4	11
47	Phenylpyridine-2-ylguanidines and rigid mimetics as novel inhibitors of TNF $\alpha$ overproduction: Beneficial action in models of neuropathic pain and of acute lung inflammation. <i>European Journal of Medicinal Chemistry</i> , 2018, 147, 163-182.	5.5	11
48	Nucleophilic Substitution of Azide Acting as a Pseudo Leaving Group: One-Step Synthesis of Various Aza Heterocycles. <i>Journal of Organic Chemistry</i> , 2013, 78, 11335-11341.	3.2	10
49	From Electronic Waste to Suzuki-Miyaura Cross-Coupling Reaction in Water: Direct Valuation of Recycled Palladium in Catalysis. <i>ChemSusChem</i> , 2020, 13, 5224-5230.	6.8	10
50	Trisubstitution of pyridine through sequential and regioselective palladium cross-coupling reactions affording analogs of known GPR54 antagonists. <i>RSC Advances</i> , 2013, 3, 10296.	3.6	9
51	CamKII inhibitors reduce mitotic instability, connexon anomalies and progression of the in vivo behavioral phenotype in transgenic animals expressing a mutated Gjb1 gene. <i>Frontiers in Neuroscience</i> , 2014, 8, 151.	2.8	9
52	Discovery of Imidazoquinazolinone Derivatives as TSPO Ligands Modulating Neurosteroidogenesis and Cellular Bioenergetics in Neuroblastoma Cells Expressing Amyloid Precursor Protein. <i>ChemistrySelect</i> , 2017, 2, 6452-6457.	1.5	9
53	Synthesis and Reactivity of 2,3-Dihydro-1H-2,3-benzodiazepine-1,4(5H)-dione. <i>Synthesis</i> , 2007, 2007, 3791-3796.	2.3	8
54	Anti-prion Drugs Targeting the Protein Folding Activity of the Ribosome Reduce PABPN1 Aggregation. <i>Neurotherapeutics</i> , 2021, 18, 1137-1150.	4.4	8

#	ARTICLE	IF	CITATIONS
55	Palladium-Catalyzed Synthesis of Substituted Pyrido[2,3-d]pyridazines at Positions 5 and 8. <i>Synthesis</i> , 2012, 44, 3216-3224.	2.3	6
56	CMTX1 patients' cells present genomic instability corrected by CamKII inhibitors. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 56.	2.7	6
57	Rapid and scalable synthesis of innovative unnatural $\alpha$ , $\beta$ or $\beta$ -amino acids functionalized with tertiary amines on their side-chains. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 7020-7026.	2.8	6
58	Development of Dipeptidic GPR54 Agonists. <i>ChemMedChem</i> , 2016, 11, 2147-2154.	3.2	6
59	Dioxygenation of styrenes with molecular oxygen in water. <i>Tetrahedron Letters</i> , 2018, 59, 1465-1468.	1.4	6
60	Synthesis and Antiproliferative Effects of 5,6-Disubstituted Pyridazin-3(2H)-ones Designed as Conformationally Constrained Combretastatin A-4 Analogues. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013, 13, 1133-1140.	1.7	6
61	Development of a Tryptophan-Based Ligand for Regioselective Copper Catalyzed N-Arylation of 1,2,3-Triazoles. <i>ChemistrySelect</i> , 2017, 2, 6544-6548.	1.5	5
62	Induction of ATP Release, PPIX Transport, and Cholesterol Uptake by Human Red Blood Cells Using a New Family of TSPO Ligands. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3098.	4.1	5
63	Design, Synthesis and Biological Evaluation of Arylpyridin-2-yl Guanidine Derivatives and Cyclic Mimetics as Novel MSK1 Inhibitors. An Application in an Asthma Model. <i>Molecules</i> , 2021, 26, 391.	3.8	5
64	N-Acyl substituted 7-amino-4-chloroisocoumarin: A peptide degradation model via an imide mechanism. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 1771-1774.	2.2	4
65	Design and validation of a homogeneous time-resolved fluorescence cell-based assay targeting the ligand-gated ion channel 5-HT3A. <i>Analytical Biochemistry</i> , 2015, 484, 105-112.	2.4	4
66	Neuropeptide FF and prolactin-releasing peptide decrease cortical excitability through activation of NPFF receptors. <i>Epilepsia</i> , 2015, 56, 489-498.	5.1	4
67	Neuropeptide FF receptors as novel targets for limbic seizure attenuation. <i>Neuropharmacology</i> , 2015, 95, 415-423.	4.1	4
68	Synthesis of 3-amino-3,4-dihydro-1H-quinolin-2-ones through regioselective palladium-catalyzed intramolecular cyclization. <i>Tetrahedron Letters</i> , 2016, 57, 1547-1550.	1.4	4
69	Identification of an N-acetylated-D-Arg-Leu-NH <sub>2</sub> Dipeptide as a Highly Selective Neuropeptide FF1 Receptor Antagonist That Potently Prevents Opioid-Induced Hyperalgesia. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 7555-7564.	6.4	4
70	$\beta$ -Space Screening of Dermorphin-Based Tetrapeptides through Use of Constrained Arylazepinone and Quinolinone Scaffolds. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 1177-1182.	2.8	4
71	Reactivity studies of 3-alkoxy-7-amino-4-chloroisocoumarins ( $\beta$ -amyloid peptide inhibitors) versus different classes of amines. <i>Organic and Biomolecular Chemistry</i> , 2003, 1, 800.	2.8	3
72	Diastereoselective Synthesis of Nonplanar 3-Amino-1,2,4-oxadiazine Scaffold: Structure Revision of Alchornedine. <i>Journal of Organic Chemistry</i> , 2020, 85, 15347-15359.	3.2	3

#	ARTICLE	IF	CITATIONS
73	<i>In Situ</i> Formation of Cationic $\eta^3$ -Allylpalladium Precatalysts in Alcoholic Solvents: Application to C–N Bond Formation. <i>ACS Catalysis</i> , 2022, 12, 560-567.	11.2	3
74	New $\beta^2$ -strand macrocyclic peptidomimetic analogues containing $\alpha$ -(O-, S- or NH-)aryl substituted glycine residues: synthesis, chemical and enzymatic properties. <i>Organic and Biomolecular Chemistry</i> , 2003, 1, 1676-1683.	2.8	2
75	CMTX Disorder and CamKinase. <i>Frontiers in Cellular Neuroscience</i> , 2016, 10, 49.	3.7	2
76	Identification of 8-Hydroxyquinoline Derivatives That Decrease Cystathionine Beta Synthase (CBS) Activity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6769.	4.1	2
77	New 2-Bromomethyl-8-substituted-benzo[c]chromen-6-ones. <i>Synthesis and Biological Properties.. ChemInform</i> , 2005, 36, no.	0.0	0
78	1-Phenyl-3H-2,3-benzodiazepin-4(5H)-one. <i>Acta Crystallographica Section E: Structure Reports Online</i> , 2012, 68, o2443-o2443.	0.2	0
79	The effect of neuropeptide FF in the amygdala kindling model. <i>Acta Neurologica Scandinavica</i> , 2016, 134, 181-188.	2.1	0